Patient-Derived Xenograft/PDX Model Market: By Model Type (Athymic Nude Mice, Severely Compromised Immune Deficient (SCID) Mice, NOD-SCID Mice, and Recombination-Activating Gene 2 (Rag2)-Knockout Mice), By Cancer Type (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Pediatric Cancer, and Other Cancers), By Application (Pre Clinical Drug Development, Precision Medicine, Basic Cancer Research, Biomarker Analysis, Immunotherapy, and Others), By End Users (Pharmaceutical And Biotechnology Industries, Contract Research Organizations (CROs), Academic and Research Institutions and Others), and Geography

Patient-Derived Xenograft/PDX Model Market size was valued at USD 253.7 Million in 2023 and is poised to grow at a CAGR of 16.3% from 2024-2030. The patient-derived xenograft/PDX models have emerged as valuable preclinical research tools in the field of oncology that enables the study of tumor biology, drug response, and personalized medicine approaches. This PDX model process involves implanting patient tumor samples into immunodeficient mice, allowing the tumors to grow and mimic the characteristics of the original patient tumors. The PDX model market has witnessed significant growth primarily due to rising prevalence of cancer. According to World Cancer Research Fund International, 18.1 million new cases of cancer were diagnosed and nearly 10 million deaths were reported in 2020 globally.

Moreover, rising demand for better preclinical models that can accurately predict patient responses to therapies further enhanced the advancement of PDX models. However, the market's expansion is constrained by the high cost and complexity associated with PDX model implementation. Furthermore, rising demand for the development of personalized medication, combined therapies and expansion of PDX model application beyond cancer offer immense opportunities for the growth of  the the patient-derived xenograft/PDX model market. Many market players are forming collaborations and taking initiatives for the augmentation of the patient-derived xenograft/PDX model market. For instance, in July 2022 to accelerate the development of novel therapeutics, specifically in immuno-oncology, GemPharmatech announced a strategic license agreement with Charles River Laboratories, Inc. for exclusive delivery of its next generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America.

Patient-Derived Xenograft/PDX Model Market Key Developments:

• In January 2021, Charles River Laboratories International, Inc. announced a strategic partnership with Cypre, Inc., a biotechnology company that is using 3D hydrogel technology, Falcon-X, to advance the understanding of the tumor microenvironment and predict therapeutic efficacy.
• In October 2019 – Crown Bioscience launched a new tumor organoid drug development platform with the potential to immensely improve the efficiency and speed of preclinical drug discovery.